Net sales of Arzerra for the second quarter of 2010 were approximately DKK 73 million, with an expected royalty payment to Genmab of approximately DKK 15 million.
Genmab A/S (Copenhagen:GEN) announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively. Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 15 million (approximately USD 2.4 million).
"We are pleased to report the first sales of Arzerra outside the US and are encouraged by the growth of Arzerra sales within the U.S.," said Prof. Jan G.J. van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Arzerra was granted accelerated approval by the FDA in October 2009, for the treatment of patients in the U.S. with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. Arzerra was launched by GSK in mid-November 2009. In April 2010, a conditional marketing authorization for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab was granted by the EU Commission.
The conversion to USD has been made using the Danish Central Bank closing spot rate on June 30, 2010 of USD 1.00 = DKK 6.0702.